ACURA PHARMACEUTICALS, INC: debt financing — Acura extends debt maturity and LTX-03 NDA deadline to Dec 31, 2025; warns of cash crunch

ACURA PHARMACEUTICALS, INC

Principal balance on AD Pharma promissory note $7,994,279 plus ~$683,000 accrued interest as of May 29, 2025.
Maturity of note extended from May 31, 2025 to December 31, 2025.
FDA NDA acceptance deadline for LTX-03 (hydrocodone/APAP) extended from May 31, 2025 to December 31, 2025 per Amendment #12.
Warrant to purchase 10M shares at $0.01 also extended to expire Dec 31, 2025.
Company states without additional financing by mid-June 2025 it will shut down or seek bankruptcy, risking total loss of shareholder value.

item 1.01 item 2.01 item 2.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

ACURA PHARMACEUTICALS, INC amended debt with Abuse Deterrent Pharma, LLC maturing December 31, 2025.

Counterparty: Abuse Deterrent Pharma, LLC
Maturity: December 31, 2025
Event: amendment

Exact text from the filing

This amendment #6 has an effective date of May 29, 2025 and changes the maturity date of the Amended Note from May 31, 2025 to December 31, 2025, at which time all principal and interest is due.

View on SEC.gov

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

ACURA PHARMACEUTICALS, INC incurred loan of $100,000 loans with Abuse Deterrent Pharma, LLC at 5.25%.

Instrument: loan
Principal: $100,000 loans
Counterparty: Abuse Deterrent Pharma, LLC
Rate: 5.25%
Event: incurrence

Exact text from the filing

On both May 2, 2025 and May 22, 2025, we received $100,000 loans from Abuse Deterrent Pharma, LLC (“AD Pharma”). These loans combined with previous loans made to the Company and combined with the $2,319,279 under the November 10, 2022 Amended Consolidated and Restated Secured Promissory Note, now has a principal balance of $7,994,279 with accrued interest of approximately $683,000 as of May 29, 2025 and bears interest at 5.25% (“Note”).

View on SEC.gov

Browse all debt financings →

Source: SEC EDGAR

accession 0001104659-25-054712

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.